Gastrointestinal cancers have high morbidity and mortality, arousing global concern. Unfortunately, the current therapeutic options are too limited and ineffective to reduce the high mortality rate. A breakthrough in therapy is urgently needed.

Arbele’s vision is to defeat gastrointestinal (GI) cancers, including stomach, pancreas, oesophagus, colon, liver and bile-duct cholangiocarcinoma, with immunotherapeutics based on breakthrough innovation. We focus on offering first-in-class and best-in-class GI cancer drugs and premium diagnostic screening platforms for early disease diagnosis and intervention.

Our founder, Dr John Luk, discovered in his research that CDH17 is a highly specific “clean target” biomarker in the GI tract and is clinically correlated to progression in GI cancers. Currently, Arbele has worldwide exclusive patent coverage for the CDH17 biomarker target, with 35 IP applications filed on the immunotherapeutic platform, as well as GI cancer diagnostics and biologics in various jurisdictions. Arbele has multiple proprietary technologies for next-generation GI cancer immunotherapy. The lead asset of Arbele, ARB202, is a humanised anti-CDH17xCD3 bispecific T-cell engager antibody, which can induce T-cell-mediated cell killing and cancer immunity. A first-in-humans clinical trial of ARB202 is underway in Australia and aims to have its first patient enrolled in April 2022.